HOLX Earnings

HOLX reported its earnings on 2026-01-29, showcasing a revenue of 1.00B against an estimate of 1.00B, resulting in a -2.07% surprise. The EPS was 1.04, surpassing the expected 1.09 by -4.59% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following HOLX's earnings announcement on 2026-01-29, the stock price moved by 0.00% on the day of the release. Over the subsequent five days, it saw a % change. Historically, HOLX's stock price tends to shift by an average of -1.83% in the 10 days leading up to earnings and -0.66% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate HOLX’s annual revenue to reach 1.00B, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.31% and EPS estimates Revise Upward by 0.47% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between HOLX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.31%, while EPS estimates moved Revise Upward by 0.47% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HOLX's stock price typically moves by -1.83% in the 10 days before its earnings and -0.66% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 1.00 and revenue of 1.00B.

Hologic's earnings call presented mixed signals: strong product development and strategic initiatives, but lowered EPS guidance and reduced revenue expectations from China. The Q&A session highlighted management's confidence in future growth, especially in Breast Health and Endomag, but lacked clarity on tariff mitigation and Fusion test contributions. With a lowered EPS and China revenue, alongside optimistic guidance and strategic growth, the overall sentiment is neutral, indicating a balanced outlook for short-term stock movement.